# US 2003/0224382 A1 · Reduced complexity nucleic acid targets and methods of using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0224382 A1
- Document ID: US20030224382A1
- Status: Published application
- Kind: A1
- Application number: 10/291,808
- Filed: 2002-11-07
- Published: 2003-12-04
- Earliest claimed: 1998-04-27
- Assignees: Sidney Kimmel Cancer Center
- Inventors: Michael McClelland; John Welsh; Thomas Trenkle
- Web page: https://patentgrep.com/patent/US20030224382A1

## CPC

- C12Q 1/6811: Selection methods for production or design of target specific oligonucleotides or binding molecules
- C12Q 1/6809: Methods for determination or identification of nucleic acids involving differential detection
- C12Q 1/6837: using probe arrays or probe chips (C12Q1/6874 takes precedence)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention provides a method of measuring the level of two or more nucleic acid molecules in a target by contacting a probe with a target comprising two or more nucleic acid molecules, wherein the nucleic acid molecules are arbitrarily sampled and wherein the arbitrarily sampled nucleic acid molecules comprise a subset of the nucleic acid molecules in a population of nucleic acid molecules; and detecting the amount of specific binding of the target to the probe. The invention also provides a method of measuring the level of two or more nucleic acid molecules in a target by contacting a probe with a target comprising two or more nucleic acid molecules, wherein the nucleic acid molecules are statistically sampled and wherein the statistically sampled nucleic acid molecules comprise a subset of the nucleic acid molecules in a population of nucleic acid molecules; and detecting the amount of specific binding of the target to the probe.

## Claims

### Claim 1

A method of measuring the level of two or more nucleic acid molecules in a target, comprising:
(a) contacting a probe with a target comprising two or more nucleic acid molecules, wherein said nucleic acid molecules are arbitrarily sampled and wherein said arbitrarily sampled nucleic acid molecules comprise a subset of the nucleic acid molecules in a population of nucleic acid molecules; and
(b) detecting the amount of specific binding of said target to said probe.

### Claim 2 (depends on 1)

The method of claim 1, wherein said target comprises one or more less abundant nucleic acid molecules of said population.

### Claim 3 (depends on 1)

The method of claim 1, wherein said less abundant nucleic acid molecule is less than 10% as abundant as the most abundant nucleic acid molecule in said population.

### Claim 4 (depends on 1)

The method of claim 1, wherein said less abundant nucleic acid molecule is less than 1% as abundant as the most abundant nucleic acid molecule in said population.

### Claim 5 (depends on 1)

The method of claim 1, wherein said less abundant nucleic acid molecule is less than 0.1% as abundant as the most abundant nucleic acid molecule in said population.

### Claim 6 (depends on 1)

The method of claim 1, wherein said less abundant nucleic acid molecule is less than 0.01% as abundant as the most abundant nucleic acid molecule in said population.

### Claim 7 (depends on 1)

The method of claim 1, wherein said target is generated using one or more arbitrary oligonucleotides.

### Claim 8 (depends on 1)

The method of claim 1, wherein said target is generated using RNA arbitrarily primed polymerase chain reaction (RAP-PCR).

### Claim 9 (depends on 1)

The method of claim 1, wherein said target is generated using differential display.

### Claim 10 (depends on 1)

The method of claim 1, wherein said target is generated using digestion-ligation.

### Claim 11 (depends on 1)

The method of claim 1, wherein said target is generated using a primer comprising an RNA polymerase promoter and an RNA polymerase.

### Claim 12 (depends on 11)

The method of claim 11, wherein said RNA polymerase is selected from the group consisting of T7 RNA polymerase, T3 RNA polymerase and SP6 polymerase.

### Claim 13 (depends on 1)

The method of claim 1, wherein said target is amplified.

### Claim 14 (depends on 13)

The method of claim 13, wherein said amplified target is generated using polymerase chain reaction.

### Claim 15 (depends on 1)

The method of claim 1, wherein said target is not amplified.

### Claim 16 (depends on 1)

The method of claim 1, wherein said probe is an array of molecules.

### Claim 17 (depends on 16)

The method of claim 16, wherein said molecules on said array are nucleic acid molecules.

### Claim 18 (depends on 16)

The method of claim 16, wherein said molecules on said array are oligonucleotides.

### Claim 19 (depends on 16)

The method of claim 16, wherein said molecules on said array are polypeptides.

### Claim 20 (depends on 16)

The method of claim 16, wherein said molecules on said array are peptide-nucleic acids.

### Claim 21 (depends on 1)

The method of claim 1, wherein said target comprises 10 or more nucleic acid molecules.

### Claim 22 (depends on 1)

The method of claim 1, wherein said target comprises 20 or more nucleic acid molecules.

### Claim 23 (depends on 1)

The method of claim 1, wherein said target comprises 50 or more nucleic acid molecules.

### Claim 24 (depends on 1)

The method of claim 1, wherein said target comprises 100 or more nucleic acid molecules.

### Claim 25 (depends on 1)

The method of claim 1, wherein said target comprises 1000 or more nucleic acid molecules.

### Claim 26 (depends on 1)

The method of claim 1, further comprising comparing said amount of specific binding of said target to said probe, wherein said amount of specific binding corresponds to an expression level of said nucleic acid molecules in said target, to an expression level of said nucleic acid molecules in a second target.

### Claim 27 (depends on 26)

The method of claim 26, wherein said expression level of said nucleic acid molecules in said second target is known.

### Claim 28 (depends on 26)

The method of claim 26, wherein said expression level of said nucleic acid molecules in said second target is determined by contacting said second target with said probe and detecting the amount of specific binding of said probe to said second target.

### Claim 29

A method of measuring the level of two or more nucleic acid molecules in a target, comprising:
(a) contacting a probe with a target comprising two or more nucleic acid molecules, wherein said nucleic acid molecules are statistically sampled and wherein said statistically sampled nucleic acid molecules comprise a subset of the nucleic acid molecules in a population of nucleic acid molecules; and
(b) detecting the amount of specific binding of said target to said probe.

### Claim 30 (depends on 29)

The method of claim 29, wherein said target comprises one or more less abundant sequences of said population.

### Claim 31 (depends on 30)

The method of claim 30, wherein said less abundant sequence is less than 10% as abundant as the most abundant sequence in said population.

### Claim 32 (depends on 30)

The method of claim 30, wherein said less abundant sequence is less than 1% as abundant as the most abundant sequence in said population.

### Claim 33 (depends on 30)

The method of claim 30, wherein said less abundant sequence is less than 0.1% as abundant as the most abundant sequence in said population.

### Claim 34 (depends on 30)

The method of claim 30, wherein said less abundant sequence is less than 0.01% as abundant as the most abundant sequence in said population.

### Claim 35 (depends on 29)

The method of claim 29, wherein said statistically sampled target is enhanced for complexity of unrelated nucleic acid molecules.

### Claim 36 (depends on 29)

The method of claim 29, wherein said target is generated using one or more statistical oligonucleotides.

### Claim 37 (depends on 36)

The method of claim 36, wherein said statistical oligonucleotides are selected based on rank of complexity binding.

### Claim 38 (depends on 36)

The method of claim 36, wherein said statistical oligonucleotides are enhanced for complexity binding.

### Claim 39 (depends on 29)

The method of claim 29, wherein said target is generated using directed statistical selection.

### Claim 40 (depends on 29)

The method of claim 29, wherein said target is generated using Monte-Carlo statistical selection.

### Claim 41 (depends on 29)

The method of claim 29, wherein said target is generated using digestion-ligation.

### Claim 42 (depends on 29)

The method of claim 29, wherein said target is generated using a primer comprising an RNA polymerase promoter and an RNA polymerase.

### Claim 43 (depends on 42)

The method of claim 42, wherein said RNA polymerase is selected from the group consisting of T7 RNA polymerase, T3 RNA polymerase and SP6 polymerase.

### Claim 44 (depends on 29)

The method of claim 29, wherein said target is amplified.

### Claim 45 (depends on 44)

The method of claim 44, wherein said amplified target is generated using polymerase chain reaction.

### Claim 46 (depends on 29)

The method of claim 29, wherein said target is not amplified.

### Claim 47 (depends on 29)

The method of claim 29, wherein said probe is an array of molecules.

### Claim 48 (depends on 47)

The method of claim 47, wherein said molecules on said array are nucleic acid molecules.

### Claim 49 (depends on 47)

The method of claim 47, wherein said molecules on said array are oligonucleotides.

### Claim 50 (depends on 47)

The method of claim 47, wherein said molecules on said array are polypeptides.

### Claim 51 (depends on 47)

The method of claim 47, wherein said molecules on said array are peptide-nucleic acids.

### Claim 52 (depends on 29)

The method of claim 29, wherein said nucleic acid target comprises 10 or more nucleic acid molecules.

### Claim 53 (depends on 29)

The method of claim 29, wherein said nucleic acid target comprises 20 or more nucleic acid molecules.

### Claim 54 (depends on 29)

The method of claim 29, wherein said nucleic acid target comprises 50 or more nucleic acid molecules.

### Claim 55 (depends on 29)

The method of claim 29, wherein said nucleic acid target comprises 100 or more nucleic acid molecules.

### Claim 56 (depends on 29)

The method of claim 29, wherein said nucleic acid target comprises 1000 or more nucleic acid molecules.

### Claim 57 (depends on 29)

The method of claim 29, further comprising comparing said amount of specific binding of said target to said probe, wherein said amount of specific binding corresponds to an abundance of said nucleic acid molecules in said target, to an abundance of said nucleic acid molecules in a second target.

### Claim 58 (depends on 57)

The method of claim 57, wherein said abundance of said nucleic acid molecules in said second target is known.

### Claim 59 (depends on 57)

The method of claim 57, wherein said abundance of said nucleic acid molecules in said second target is determined by contacting said second target with said probe and detecting the amount of specific binding of said probe to said second target.

### Claim 60 (depends on 1)

A method of identifying two or more differentially expressed nucleic acid molecules associated with a condition, comprising:
(a) measuring the level of two or more nucleic acid molecules in a target according to the method of claim 1, wherein said amount of specific binding of said target to said probe corresponds to an expression level of said nucleic acid molecules in said target;
(b) comparing said expression level of said nucleic acid molecules in said target to an expression level of said nucleic acid molecules in a second target, whereby a difference in expression level between said targets indicates a condition.

### Claim 61 (depends on 60)

The method of claim 60, wherein said condition is associated with a disease state.

### Claim 62 (depends on 60)

The method of claim 60, wherein said disease state is selected from the group consisting of cancer, autoimmune disease, infectious disease, aging, developmental disorder, proliferative disorder, neurological disorder.

### Claim 63 (depends on 60)

The method of claim 60, wherein said condition is associated with a treatment.

### Claim 64 (depends on 63)

The method of claim 63, wherein said difference in expression level indicates an efficacy of said treatment.

### Claim 65 (depends on 63)

The method of claim 63, wherein said difference in expression level indicates a resistance to said treatment.

### Claim 66 (depends on 63)

The method of claim 63, wherein said difference in expression level indicates a toxicity of said treatment.

### Claim 67 (depends on 60)

The method of claim 60, wherein said condition is associated with a stimulus.

### Claim 68 (depends on 67)

The method of claim 67, wherein said stimulus is a chemical.

### Claim 69 (depends on 68)

The method of claim 68, wherein said chemical is a drug.

### Claim 70 (depends on 67)

The method of claim 67, wherein said stimulus is a growth factor.

### Claim 71 (depends on 67)

The method of claim 67, wherein said growth factor is epidermal growth factor (EGF).

### Claim 72 (depends on 71)

The method of claim 71, wherein said target comprises a portion of a nucleic acid sequence selected from the group consisting of nucleic acids referenced as SEQ ID NOS:1-45.

### Claim 73 (depends on 67)

The method of claim 67, wherein said stimulus is radiation.

### Claim 74 (depends on 67)

The method of claim 67, wherein said stimulus is stress.

### Claim 75 (depends on 60)

The method of claim 60, wherein said target is derived from skin cells.

### Claim 76 (depends on 75)

The method of claim 75, wherein said skin cells comprise keratinocytes.

### Claim 77 (depends on 60)

The method of claim 60, wherein said target is derived from a tumor.

### Claim 78 (depends on 67)

The method of claim 67, wherein said stimulus is a pathogen.

### Claim 79

A profile comprising five or more stimulus-regulated nucleic acid molecules.

### Claim 80 (depends on 79)

The profile of claim 79, wherein said profile comprises ten or more stimulus-regulated nucleic acid molecules.

### Claim 81 (depends on 79)

The profile of claim 79, wherein said profile comprises 100 or more stimulus-regulated nucleic acid molecules.

### Claim 82 (depends on 79)

The profile of claim 79, wherein said profile comprises 1000 or more stimulus-regulated nucleic acid molecules.

### Claim 83 (depends on 80)

The profile of claim 80, wherein said stimulus is epidermal growth factor.

### Claim 84 (depends on 83)

The profile of claim 83, comprising a portion of a nucleotide sequence selected from the group consisting of the nucleotide sequences referenced as SEQ ID NOS:1-45.

### Claim 85 (depends on 1)

A profile obtained by the method of claim 1.

### Claim 86 (depends on 85)

The profile of claim 85, wherein said profile comprises two or more nucleic acid molecules.

### Claim 87 (depends on 85)

The profile of claim 85, wherein said profile comprises 5 or more nucleic acid molecules.

### Claim 88 (depends on 85)

The profile of claim 85, wherein said profile comprises 10 or more nucleic acid molecules.

### Claim 89 (depends on 85)

The profile of claim 85, wherein said profile comprises 100 or more nucleic acid molecules.

### Claim 90 (depends on 29)

A profile obtained by the method of claim 29.

### Claim 91 (depends on 90)

The profile of claim 90, wherein said profile comprises two or more nucleic acid molecules.

### Claim 92 (depends on 90)

The profile of claim 90, wherein said profile comprises 5 or more nucleic acid molecules.

### Claim 93 (depends on 90)

The profile of claim 90, wherein said profile comprises 10 or more nucleic acid molecules.

### Claim 94 (depends on 90)

The profile of claim 90, wherein said profile comprises 100 or more nucleic acid molecules.

### Claim 95

A target comprising a portion of each of the nucleotide sequences referenced as SEQ ID NOS:1-45.
